본문
[IL2112] ACKR3 PAM for Autoimmune and Fibrotic Diseases
ØACKR3 PAM: Game Changing
First-in-Class with a Unique MoA:
•The
ACKR3 PAM binds with the ACKR3 receptor and increases its affinity for the
CXCL12 which enables ACKR3 to internalize and degrade CXCL12 intracellularly,
leading to the reduction and normalization of the CXCL12 level, a key chemokine
involved in immune cell recruitment and chronic inflammation, and its
dysregulation is implicated in various autoimmune diseases, including
rheumatoid arthritis
•Anti-fibrosis,
anti-inflammation, and tissue regeneration
ØAddressing Significant Unmet Needs:
•Targets fibrotic and autoimmune diseases
where SoCs either do not exist or limited to suboptimal efficacy and/or
unfavorable safety profile
•CXCL12 could serve as a biomarker to
identify the target patient pool and manage disease progression through simple
blood collection
ØCompelling Non-clinical Data:
•Strong efficacy observed consistently
across various fibrosis (lung, liver, kidney, cardiac, and skin) and autoimmune
(RA, IBD, MS) models
•Favorable oral PK profile with a long
half-life, enabling a once-a-day, oral formulation
•Favorable safety profile observed in over
10 acute & chronic animal models where animals were dosed with our drug for
up to 3 months
ØDevelopment Strategy:
•Pursue approval for autoimmune
indications (RA is main indication) first prior to expanding to fibrotic
indications
ØKey Milestones:
•IND
filing (4Q 2025 ~ 1Q 2026; Anticipated)